

Tralyte +health

Electrolyte Insight on Demand



The First Home Electrolyte Monitoring Platform

September 2026

PRIVATE & CONFIDENTIAL – FOR DISCUSSION PURPOSES

TRALYTE HEALTH LEADERSHIP TEAM



Jay Atkinson, MBA
Chief Executive Officer

Jay Atkinson is a technology executive, entrepreneur, MBA, and former CPA with extensive experience in company building, strategic planning, fundraising, and operations. As CEO of Tralyte Health, Jay leads corporate strategy, financing, partnerships, and commercialization efforts as the company develops the first home electrolyte monitoring platform and advances toward regulatory clearance and market entry.



Dr. Rick Siira, MD, MPH
Chief Medical Officer

Dr. Rick Siira is an emergency physician with extensive experience translating clinical needs into practical healthcare solutions. At Tralyte, he leads clinical strategy, validation planning, and regulatory preparation, helping ensure the platform delivers clinically actionable data.



Dr. Xuewei Wang, Ph.D.
Inventor

Dr. Xuewei Wang is an award-winning Associate Professor of Chemistry at Virginia Commonwealth University and inventor of Tralyte Health's patent-pending Ultrasensitive Separation-Free Blood Testing Technology (PCT/US23/65882). Dr. Wang has secured over \$3.5M in research funding, including NIH R01 and R21 grants. He leads scientific development of the Tralyte electrolyte sensing platform.



Laurie Head
Chief Communications Officer

Laurie Head is a technology executive and award-winning communications leader with expertise in public affairs, strategic partnerships, investor communications, and stakeholder engagement. At Tralyte, she leads patient and advocacy group engagement, external communications, and partnership development, helping build awareness, credibility, and adoption across the broader healthcare ecosystem.

VIDEO



► [Click image or here to watch the YouTube video](https://youtu.be/Wlz8Hpon3f0?si=0rsEHLMxiypoQQqe)

Direct Link: <https://youtu.be/Wlz8Hpon3f0?si=0rsEHLMxiypoQQqe>

THE PROBLEM

Electrolytes Drive Clinical Testing — But Testing Is Still Trapped In Labs

Calcium (Ca^{2+})

- Hypoparathyroidism
- Muscle Function
- Neuromuscular Stability

Potassium (K^+)

- Kidney Disease
- Dialysis
- Cardiac Risk

Sodium (Na^+)

- Hydration
- Endurance
- Performance
- Heart Failure

Magnesium (Mg^{2+})

- Cardiac Function
- Recovery
- Metabolic Health



Billions of Electrolyte Tests Are Performed Annually....

Yet there is no FDA-cleared home electrolyte monitoring platform.
Tralyte is building the first home electrolyte monitoring platform, starting with calcium.

Building the First Home Electrolyte Monitoring Platform, Starting With Calcium

Clinical urgency

- Hypopara patients need frequent monitoring.
- New therapies are increasing demand.

No validated in-home competition

- No FDA-cleared home calcium monitor.
- Tralyte technology makes home monitoring possible.

Fastest validation path

- Strong patient demand and pharma interest.

Hypopara is not our destination market. It is our validation market.



THE SOLUTION

The Tralyte Platform Provides the First Lab-Grade, at-Home Calcium Test

Hypopara patients can self-test, anytime or anywhere, and get real-time calcium insight from a single drop of blood.

No labs. No delays.
Just real time insight.

THE TECHNOLOGY

A Lab Grade Diagnostics Platform for the Home



Lab-proven for calcium
Patent-pending
Peer-reviewed



One drop of blood
(5-10 μL)



Results in 15 minutes
for single or multiple
analytes



Use anywhere – no lab or
lab techs required



Handheld Device





Disposable Chip



Smart Phone App

Clinical Validation: Lab-Comparable Accuracy



- Validated in 51 human blood samples against a clinical reference method.
- 84% of samples measured within 5% of reference lab results.
- Demonstrated strong agreement across the clinically relevant calcium range.
- Consistent triplicate testing demonstrated precision and repeatability.
- Peer-reviewed in *Analytical Chemistry* (2023).

Scientific Foundation & Platform Defensibility

Foundation

- Built on Peer-Reviewed Science, Published in *Analytical Chemistry* (2023)
- Developed at VCU over multiple years
- Validated in human blood samples across clinical ranges
- Supported by NIH and institutional research funding

Patent-Protected Platform


- Patent-pending (PCT/US23/65882)
- Novel sensing architecture
- No calibration required vs. traditional sensors
- Extensible to potassium, sodium, magnesium, lithium
- Platform capable of full metabolic panel over time

Nearly \$2M invested in developing and validating the underlying science prior to company formation by NIH, BridgeBio, the Orphan Disease Center, and VCU.

STRATEGIC PATH TO MULTIPLE MARKETS

Platform Expansion Roadmap

One sensing platform. Multiple markets.



Calcium validates the platform. Potassium scales the platform.
The same sensing platform can be extended to K^{+} in ~6 months with ~\$150k of additional development.

MARKET POTENTIAL

Beachhead: Hypoparathyroidism

Why Hypopara First?

High Clinical Need

- Frequent monitoring required

No Competition

- No FDA-cleared home calcium monitor

Strong Market Pull

- Patients, clinicians, advocacy groups

Pharma Alignment

- Next-generation PTH therapies increase monitoring demand
- Public statements and direct discussions with leading HypoPT therapy developers have reinforced the need for at-home calcium monitoring.

Key Trends Driving Hypopara Growth Trajectory

***Platform
Validation
Market -
\$500M Global
TAM***

Patient Demand

***<96% support
for home
calcium
monitor***

Rising Diagnoses

***~90k in U.S.,
<870k
worldwide***

Innovative Therapies

***1 drug in
market + 5 in
pipeline***

***Focused Market. High Need. Low Competition.
Large Share Opportunity.***

MARKET POTENTIAL

Expansion Opportunity: Potassium Monitoring

Why Potassium?

Same Platform

- Same sensing architecture
- Same handheld device
- Same cartridge model
- Same patient workflow

High Clinical Need

- Potassium drives treatment decisions
- Hyperkalemia can be life-threatening
- Millions already require monitoring

No Home Market Leader

- Testing remains largely lab-based
- No FDA-cleared home potassium monitor

Large Existing Potassium Markets

***\$1B+ US
Potassium
Monitoring
Opportunity***

CKD
37M US Adults
Largest
addressable
sub-market

**Heart
Failure**
6.7M US
Patients
Potassium
critical for
medication
management

Dialysis
550k US Patients
Frequent
Potassium
Monitoring

***Natural Expansion From Calcium –
Same Platform, Device, and Workflow.
Calcium Validates the Platform. Potassium Scales the Platform.***

Longitudinal Data Becomes a Strategic Asset



Patient-First Impact

Enables safer, more stable calcium management between clinic visits

Clinical Learning at Scale

Builds one of the first datasets on real-world calcium dynamics in HypoPara management

Designed for Trust

De-identified, consent-driven data use aligned with patient benefit

TralyteCare Traction and Momentum

Upcoming Milestones

- Tralyte showcase at International HypoPARA Conference (Sept. 2026)


Strategic Validation

- BridgeBio funded foundational research supporting the technology.
- Active discussions with leading HypoPT therapy developers.
- Both public statements and direct discussions with therapy developers reinforce the need for at-home calcium monitoring.


Financial & Ecosystem Support



Commercialization, Research & Advocacy Support



Capital to Market & Milestones



Revenue Model

Calcium Validation and Potassium Expansion

Includes:


- Calcium monitoring (hypopara)
- Potassium monitoring (dialysis)
- Device sales
- Recurring consumables

Not Included:

- Potassium monitoring for CKD and heart failure
- Additional electrolytes (sodium, magnesium, lithium)
- Data licensing revenue

TralyteCare

Calcium Validation and Potassium Expansion



The Ask

Currently raising \$2M in a pre-seed round. Use of funds:

- Complete alpha-to-beta device development
- Conduct validation studies
- Advance FDA engagement and submission preparation
- Build software and data infrastructure
- Demonstrate platform extensibility, including potassium feasibility

This raise is designed to de-risk the platform through commercialization of its first application: calcium monitoring.

SUMMARY



**The Science
Is
Done.**

**The Market
Is
Pulling.**

**The Key
Is
Tralyte +health**

Electrolyte Insight on Demand



Contact

Jay Atkinson
CEO
Tralyte Health

jay@tralytehealth.com
703.304.1523